In the BioHarmony Drug Report Database
Nafarelin
Synarel (nafarelin) is a protein pharmaceutical. Nafarelin was first approved as Synarel on 1990-02-13. It is used to treat endometriosis and precocious puberty in the USA. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Trade Name
|
Synarel |
|---|---|
Common Name
|
nafarelin |
ChEMBL ID
|
CHEMBL1201309 |
Indication
|
endometriosis, precocious puberty |
Drug Class
|
Prehormones or hormone-release stimulating peptides |
Image (chem structure or protein)